Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries

Bevacizumab became the first molecular antibody to show survival benefit in advanced cervical cancer. In the GOG-0240 (Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer) trial, it improved overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyawali, Bishal, Iddawela, Mahesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493276/
https://www.ncbi.nlm.nih.gov/pubmed/28717748
http://dx.doi.org/10.1200/JGO.2016.004895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493276/
https://www.ncbi.nlm.nih.gov/pubmed/28717748
http://dx.doi.org/10.1200/JGO.2016.004895

Ejemplares similares